Keeps Company Overview and Business Model

What Keeps Actually Is

Keeps operates as a telehealth intermediary that connects men experiencing androgenetic alopecia with licensed physicians who can prescribe FDA-approved treatments. The company does not manufacture medications. It contracts with licensed pharmacies to dispense generic finasteride and branded or generic minoxidil formulations, then ships them on a recurring schedule.

The platform launched in 2018 during the first wave of men's telehealth startups. Unlike traditional dermatology referrals that require in-person scalp examinations, Keeps uses an asynchronous model: patients upload photos of their hairline and crown, answer a medical questionnaire, and a physician reviews the submission within 24-48 hours. If appropriate, the physician writes a prescription that Keeps fulfills through its pharmacy partners.

This model works because androgenetic alopecia has a characteristic pattern that experienced clinicians can identify photographically. The Hamilton-Norwood scale, used since 1975, classifies male pattern hair loss into seven stages based on visual assessment alone [1]. A 2019 study in the Journal of the American Academy of Dermatology confirmed that teledermatology consultations for hair loss achieved diagnostic concordance with in-person visits in 83% of cases [2].

Is Keeps Legit? Evaluating the Clinical Foundation

The short answer: yes, Keeps prescribes real medications with strong clinical evidence. The company's legitimacy rests entirely on the drugs it dispenses, not on any proprietary formulation.

Finasteride 1 mg, Keeps' primary prescription, received FDA approval for male pattern hair loss in 1997 under the brand name Propecia. The key trials showed that 83% of men maintained or increased hair count after two years versus 28% on placebo [3]. A five-year extension study demonstrated sustained efficacy, with 90% of finasteride-treated men showing visible improvement compared to baseline photographs [4].

Minoxidil 5% topical solution, Keeps' second core product, has been available over-the-counter since 1996. The original Olsen et al. trial (N=393) demonstrated that 5% minoxidil produced 45% more hair regrowth than 2% minoxidil at 48 weeks [5]. Because minoxidil is OTC, prescribing it through a telehealth platform is technically unnecessary. Patients could purchase identical formulations at any pharmacy. Keeps bundles it for convenience.

Where legitimacy questions arise is not in the medications but in the consultation model. The American Academy of Dermatology's position statement on teledermatology notes that asynchronous store-and-forward consultations are appropriate for conditions where visual diagnosis is well-established [6]. Androgenetic alopecia fits this criterion. However, conditions that mimic pattern hair loss (telogen effluvium, alopecia areata, thyroid disorders) can sometimes be missed without laboratory workup or physical examination.

The Business Model: How Keeps Makes Money

Keeps generates revenue through three mechanisms. Subscription markup on generic medications is the primary driver. Generic finasteride 1 mg costs pharmacies approximately $0.20-0.50 per tablet at wholesale. A 90-day supply at retail with a GoodRx coupon runs $9-15 at most chain pharmacies. Keeps charges $25/month for finasteride alone, which prices to $75 per quarter.

The second revenue stream is bundling. Keeps encourages combination therapy (finasteride plus minoxidil) at $49-75/month. This bundling is clinically defensible. A randomized controlled trial by Hu et al. (N=984) demonstrated that combination finasteride plus minoxidil produced superior hair density gains compared to either agent alone at 12 months [7]. But the price premium over purchasing each generic separately is substantial.

Third, Keeps monetizes the consultation itself. The physician review is included in the subscription cost, but it represents a real service. A traditional dermatology visit for hair loss costs $150-300 out of pocket without insurance. Keeps amortizes this cost across monthly payments, making the initial barrier to treatment lower.

The company has raised over $80 million in venture funding. Their unit economics depend on long subscriber retention, which aligns with the clinical reality that finasteride and minoxidil require continuous use to maintain results. Discontinuation leads to resumed hair loss within 6-12 months [8].

Keeps Pricing Breakdown vs. Alternatives

A direct cost comparison reveals where Keeps sits in the market. For finasteride 1 mg (30 tablets): Keeps charges approximately $25/month. The same generic at Costco pharmacy with a GoodRx coupon costs $5-8/month. Roman (Ro) charges $20-30/month. Hims prices at $23-30/month.

For topical minoxidil 5% (one month supply): Keeps charges $10-15/month when bundled. Kirkland brand (Costco) retails at $6-8/month. Amazon generics run $7-12/month. The Cochrane systematic review of minoxidil (17 included trials, N=3,820) found no clinically meaningful differences between branded and generic formulations [9].

The premium Keeps charges covers three things: physician access, shipping convenience, and treatment monitoring through periodic photo reviews. Whether that premium is worth it depends on the patient's insurance situation, proximity to a pharmacy, and comfort level with self-managing a straightforward medication regimen.

For men without insurance who want a physician's oversight without an in-person visit, Keeps represents a reasonable middle ground. For men comfortable asking their primary care physician for a finasteride prescription (a two-minute conversation), the generic pharmacy route saves $15-20/month indefinitely.

What Keeps Prescribes: The Full Formulary

Keeps' prescribing menu is narrow by design. The platform focuses exclusively on two FDA-approved compounds for androgenetic alopecia.

Oral finasteride 1 mg inhibits type II 5-alpha reductase, reducing scalp dihydrotestosterone (DHT) by approximately 64% at steady state [10]. The FDA label indicates it for male pattern hair loss in men only. Sexual side effects (decreased libido, erectile dysfunction) occurred in 1.3-1.8% of men in key trials versus 0.7-1.3% on placebo [3].

Topical minoxidil 5% is a potassium channel opener that prolongs anagen phase and increases follicular blood flow. Applied twice daily, it produces measurable hair count increases within 4-6 months [5]. Contact dermatitis is the primary adverse effect, occurring in 5-7% of users.

Topical finasteride (more recently added) delivers finasteride directly to the scalp. A phase II trial by Piraccini et al. demonstrated that topical finasteride 0.25% reduced scalp DHT comparably to oral finasteride while producing 50-70% lower serum DHT suppression [11]. This may reduce systemic side effect risk, though long-term comparative safety data remains limited.

Keeps does not prescribe dutasteride, spironolactone, or compounded formulations that some competitors offer. This conservative formulary limits their utility for advanced hair loss cases but keeps their clinical risk profile straightforward.

Keeps vs. Competitors: Where It Fits

The D2C telehealth hair loss market includes Hims, Roman (Ro), Happy Head, and Thirty Madison's Facet brand. Differentiation between these platforms is minimal because they all prescribe the same FDA-approved medications.

Keeps differentiates primarily on price (slightly lower than Hims for finasteride-only plans) and marketing positioning (clinical seriousness rather than lifestyle branding). Hims offers a broader product range including supplements, topical serums, and combination sprays. Roman integrates hair loss into a wider men's health platform including ED and weight management.

Happy Head represents the most clinically aggressive competitor, offering compounded topical formulations containing finasteride, minoxidil, tretinoin, and sometimes latanoprost in a single vehicle. These compounded preparations lack individual FDA approval but combine drugs each supported by evidence. A pilot study of topical latanoprost for alopecia showed modest hair density increases [12], though evidence remains preliminary.

For the average Norwood II-III patient seeking first-line therapy, functional differences between Keeps, Hims, and Roman are negligible. The medications are identical. The choice comes down to pricing, UI preference, and whether you want a platform that also handles other health concerns.

Treatment Efficacy: What the Evidence Actually Shows

Patients considering Keeps should understand what finasteride and minoxidil can and cannot accomplish. These drugs work best for early-to-moderate hair loss. They maintain existing hair more reliably than they regrow lost hair.

The Norwood classification study database indicates that men at Norwood II-IV respond best to medical therapy [1]. By Norwood V-VII, the miniaturized follicles have often undergone terminal fibrosis, making pharmacologic rescue unlikely. Keeps' photo-based assessment should theoretically screen out advanced cases that would not benefit, but patient satisfaction data on this filtering is not publicly available.

Time to visible results is 4-6 months minimum. The hair growth cycle means that finasteride's DHT-lowering effect must persist through at least one full anagen phase (2-6 years in duration, but early anagen changes become photographically detectable at 4-6 months). The Kaufman et al. five-year data showed progressive improvement through year two, with plateau thereafter [4].

Adherence is the primary predictor of outcome. A retrospective analysis of 2,561 finasteride users found that men who maintained therapy for more than 12 months had significantly better outcomes than those who discontinued before month six [13]. The subscription model Keeps uses may actually improve adherence through automatic refills and reduced friction, though no head-to-head data confirms this hypothesis.

Safety Considerations and Limitations

The safety profile of Keeps' medications is well-characterized but requires honest discussion. Finasteride's sexual side effects are the primary concern.

In the original Merck trials, 3.8% of finasteride users reported any sexual adverse event versus 2.1% on placebo [3]. The absolute risk increase is small. However, post-marketing reports of persistent sexual side effects after discontinuation ("post-finasteride syndrome") have generated controversy. The Endocrine Society's 2019 position acknowledged these reports while noting that controlled prospective studies have not confirmed a causal mechanism for persistent effects [14].

Keeps' asynchronous model has inherent limitations for safety monitoring. If a patient develops side effects, they must proactively report them through the platform rather than being assessed at a follow-up visit. The platform does provide messaging access to their physicians, but the response time and depth of evaluation cannot match an in-person relationship.

Men under 18, women, and men with liver disease should not use finasteride. Keeps' intake questionnaire screens for these contraindications, but the accuracy of self-reported medical history in any telehealth context remains a systemic limitation across the industry, not unique to Keeps.

The Verdict: Who Should Consider Keeps

Keeps serves a specific patient profile well: men aged 18-45 with early-to-moderate androgenetic alopecia (Norwood II-IV) who want physician-supervised FDA-approved treatment without scheduling a dermatology appointment. The convenience premium over generic pharmacy purchasing is $15-20/month.

Men who should look elsewhere include those with advanced hair loss (Norwood V+), those experiencing sudden or patchy hair loss (which warrants in-person evaluation to rule out autoimmune or systemic causes), and those seeking aggressive multi-agent protocols that exceed Keeps' conservative formulary.

The platform is not a scam. It is also not revolutionary. Keeps packages established, FDA-approved medications into a subscription service with a telehealth consultation layer. The clinical outcomes patients achieve on Keeps will be identical to those achieved purchasing the same generics from a local pharmacy with a PCP prescription. You are paying for convenience, not superior medicine.

For a 30-year-old man noticing crown thinning who has never discussed it with a doctor, Keeps removes a real barrier: the awkwardness and scheduling friction of bringing up hair loss at a primary care visit. That convenience has genuine value. Whether it is worth $25-75/month more than the pharmacy alternative is a personal calculation, not a medical one.